Bluejay Diagnostics (NASDAQ:BJDX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Bluejay Diagnostics (NASDAQ:BJDX) from a sell rating to a hold rating in a research report released on Sunday morning,Wall Street Zen reports.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Bluejay Diagnostics has a consensus rating of “Sell”.

Bluejay Diagnostics Trading Up 23.7%

Shares of NASDAQ BJDX opened at $1.03 on Friday. The company has a market cap of $4.60 million, a price-to-earnings ratio of -0.14 and a beta of 0.91. Bluejay Diagnostics has a 12 month low of $0.82 and a 12 month high of $16.68. The stock has a 50-day moving average price of $1.07 and a two-hundred day moving average price of $1.94.

Bluejay Diagnostics (NASDAQ:BJDX) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($1.12) EPS for the quarter, beating analysts’ consensus estimates of ($3,520.00) by $3,518.88.

Insider Buying and Selling

In other Bluejay Diagnostics news, major shareholder Financial Lp Hrt sold 34,938 shares of Bluejay Diagnostics stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $1.40, for a total value of $48,913.20. Following the completion of the sale, the insider directly owned 92,055 shares in the company, valued at approximately $128,877. The trade was a 27.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 6.10% of the stock is owned by corporate insiders.

Institutional Trading of Bluejay Diagnostics

A hedge fund recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC acquired a new stake in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned approximately 9.15% of Bluejay Diagnostics as of its most recent SEC filing. Hedge funds and other institutional investors own 18.47% of the company’s stock.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.